
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
ICON plc has announced that it has acquired a majority shareholding in MeDiNova Research, a site network with research sites in Europe and Africa, and that it has the right to acquire the remaining shares in the company by Quarter Three 2020. MeDiNova Research currently has a network of 33 active clinical research sites in the UK, Spain, South Africa, Poland and Romania.
For more information click






